Ken Griffin Apellis Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $253,792 - $362,120	8,800 Added 5.11%	181,100 $5.22 Million
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $4.6 Million - $7.21 Million	-120,700 Reduced 41.19%	172,300 $6.61 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $6.39 Million - $8.36 Million	-115,400 Reduced 28.26%	293,000 $17.2 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $3.71 Million - $6.48 Million	99,900 Added 32.38%	408,400 $24.4 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $2.2 Million - $8.29 Million	92,900 Added 43.09%	308,500 $11.7 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $2.2 Million - $2.68 Million	28,700 Added 15.36%	215,600 $19.6 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $409,992 - $589,248	-8,800 Reduced 4.5%	186,900 $12.3 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $4.39 Million - $6.2 Million	101,500 Added 107.75%	195,700 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.36 Million - $2.11 Million	30,300 Added 47.42%	94,200 $6.43 Million

309

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.38B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.